Helix BioPharma to Present at Q3 2025 Investor Summit
Toronto, Ontario — September 9, 2025 — Leads & Copy — Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, highlighting its preparation for a Phase Ib/Randomized Phase II clinical study of L-DOS47 and its planned NASDAQ uplisting in Q1 2026.
The Investor Summit, an exclusive quarterly virtual event for investors specializing in small and microcap stocks, emphasizes undervalued MicroCap companies with strong growth catalysts. Helix aims to accelerate oncology asset development and broaden its visibility to global capital markets.
Investors can book one-on-one meetings with Thomas Mehrling, MD, PhD, CEO of Helix BioPharma. The event, running from September 16 to 17, includes company presentations, live Q&A, and one-on-one meetings.
Event details include the presentation on September 16 at 2:30 PM ET. The webcast link is https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/ and investor registration is free at https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus.
Helix BioPharma’s pipeline is led by Tumor Defense Breaker™ L-DOS47. The company is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0).
Contact: Thomas Mehrling, CEO, corporate@helixbiopharma.com, Tel: +1 857 208 7687
Source: Helix BioPharma
Share this story:
